Proficio Capital Partners LLC Invests $2.92 Million in Vaxcyte, Inc. (NASDAQ:PCVX)

Proficio Capital Partners LLC bought a new position in Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 35,609 shares of the company's stock, valued at approximately $2,915,000.

Other institutional investors and hedge funds have also modified their holdings of the company. Whipplewood Advisors LLC bought a new position in Vaxcyte in the 4th quarter worth approximately $28,000. Blue Trust Inc. raised its position in Vaxcyte by 100.0% in the 4th quarter. Blue Trust Inc. now owns 742 shares of the company's stock worth $61,000 after purchasing an additional 371 shares during the last quarter. Meeder Asset Management Inc. raised its position in Vaxcyte by 1,007.9% in the 3rd quarter. Meeder Asset Management Inc. now owns 698 shares of the company's stock worth $80,000 after purchasing an additional 635 shares during the last quarter. Nomura Asset Management Co. Ltd. bought a new position in Vaxcyte in the 3rd quarter worth approximately $92,000. Finally, AlphaCentric Advisors LLC bought a new position in Vaxcyte in the 4th quarter worth approximately $161,000. 96.78% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, CEO Grant Pickering sold 2,366 shares of the business's stock in a transaction on Monday, December 9th. The shares were sold at an average price of $92.25, for a total value of $218,263.50. Following the completion of the transaction, the chief executive officer now owns 136,215 shares of the company's stock, valued at $12,565,833.75. The trade was a 1.71 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Andrew Guggenhime sold 8,000 shares of the business's stock in a transaction on Wednesday, December 18th. The shares were sold at an average price of $88.78, for a total transaction of $710,240.00. Following the completion of the transaction, the chief financial officer now directly owns 109,491 shares of the company's stock, valued at $9,720,610.98. This trade represents a 6.81 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 56,616 shares of company stock valued at $4,768,521 in the last quarter. Company insiders own 3.10% of the company's stock.

Remove Ads

Analyst Upgrades and Downgrades

PCVX has been the subject of several research analyst reports. Needham & Company LLC restated a "buy" rating and issued a $140.00 price objective on shares of Vaxcyte in a research report on Wednesday, February 26th. The Goldman Sachs Group initiated coverage on shares of Vaxcyte in a research report on Friday, December 20th. They issued a "buy" rating and a $135.00 price objective for the company. Finally, Guggenheim restated a "buy" rating and issued a $160.00 price objective on shares of Vaxcyte in a research report on Wednesday, February 26th. Nine research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has an average rating of "Buy" and a consensus target price of $147.50.

Vaxcyte Price Performance

Shares of Vaxcyte stock traded down $3.63 on Friday, hitting $71.18. 1,355,596 shares of the company's stock traded hands, compared to its average volume of 1,195,973. The firm's 50-day moving average price is $83.33 and its two-hundred day moving average price is $94.62. The stock has a market capitalization of $9.17 billion, a PE ratio of -15.47 and a beta of 1.02. Vaxcyte, Inc. has a one year low of $58.10 and a one year high of $121.06.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last issued its earnings results on Tuesday, February 25th. The company reported ($1.02) EPS for the quarter, beating the consensus estimate of ($1.16) by $0.14. On average, analysts forecast that Vaxcyte, Inc. will post -4.21 earnings per share for the current fiscal year.

Vaxcyte Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.